Diagnostics and methods for prognosing response to immunotherapy based on the methylation status of immune synapse gene signature
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsSungjune KIM, Anders BERGLUND
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for using the methylation status of a cancerous tissue to assess the susceptibility of a cancer to immunotherapy and determine new treatment regimens. Disclosed are methods related to producing an immunotherapeutic regimen based on the amount of methylation in co-stimulatory genes and/or immune checkpoint genes, as well as, methods of treating an immunogenic cancer based on the same.
Claims22
A method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis in a subject comprising:
- a. obtaining a tissue sample from the subject;
- b. assaying the amount of methylation of one or more co-stimulatory genes and/or one or more immune checkpoint genes in the tissue sample;
- and
- c. administering to the subject an immunotherapy wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue is detected and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue is detected.
A method of assessing the suitability of an immunotherapy treatment regimen for the treatment an immunogenic cancer or metastasis in a subject comprising:
- a. obtaining a tissue sample from the subject;
- and
- b. assaying the amount of methylation of one or more co-stimulatory genes and/or one or more immune checkpoint genes in the tissue sample;
- wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that immunotherapy is suitable for treatment of the cancer in the subject.
Dependencies are inferred from the claim text.